Grant: O. Gr.: Addr. the Health Impacts of COVID-19 - Imp. of def/disp care on health
University of British Columbia
$497,320.00
The impact of COVID-19 and related control measures on the hepatitis C virus care cascade
FY 2021-22
Summary
Measures taken to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission have limited access to healthcare services worldwide. Declining testing volumes, diagnosis and treatment rates for blood-borne infections such as hepatitis C virus (HCV) were reported in England during early phases of the coronavirus disease 2019 (COVID-19) pandemic, showing significant disruptions in healthcare provision for these illnesses. These disruptions may have long-term implications for people who already face barriers to accessing care and are at increased risk of infection, complications and death, including people who inject drugs (PWID), who are also affected by the ongoing opioid overdose crisis; gay, bisexual, and other men who have sex with men (gbMSM); immigrants; and incarcerated persons. HCV care cascades can identify gaps in healthcare service provision along the HCV care journey, including: (i)antibody diagnosis, (ii)ribonucleic acid (RNA) testing, (iii)RNA positive diagnosis, (iv)genotyping, (v)treatment and (vi)cure. Large declines in HCV testing and diagnosis rates were reported in British Columbia (BC) and Ontario (ON) at the start of the pandemic, however comprehensive data on the full care cascade are currently unavailable. Data is also lacking on pandemic related changes in HCV care in other Canadian provinces, which are needed to assess and mitigate the effect of the pandemic impacts on the health of people living with HCV in Canada, especially among priority populations. Using testing and administrative data from BC and ON, this project aims to assess the impact of the COVID-19 pandemic and related control measures on (i)HCV care cascades in BC and ON; and (ii)HCV reinfection and death among PWID, gbMSM and immigrants. Surveys conducted among people from priority populations listed above and among healthcare providers will complement care cascade data and provide details on, and practical solutions to, on-the-ground impacts of the pandemic.
Department
Program
O. Gr.: Addr. the Health Impacts of COVID-19 - Imp. of def/disp care on health
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
460264
Name
Janjua Naveed Z
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Health systems / services
Prcname2
Operating Grant : Addressing the Wider Health Impacts of COVID-
Projecttitle
The impact of COVID-19 and related control measures on the hepatitis C virus care cascade
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$497,320
Cihrequipment2
$0
Programname2
O. Gr.: Addr. the Health Impacts of COVID-19 - Imp. of def/disp care on health
Keyworddelim
Care Cascade; Hepatitis C; Marginalized Populations; People Who Inject Drugs; Unintended Consequences
Abstract
Measures taken to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission have limited access to healthcare services worldwide. Declining testing volumes, diagnosis and treatment rates for blood-borne infections such as hepatitis C virus (HCV) were reported in England during early phases of the coronavirus disease 2019 (COVID-19) pandemic, showing significant disruptions in healthcare provision for these illnesses. These disruptions may have long-term implications for people who already face barriers to accessing care and are at increased risk of infection, complications and death, including people who inject drugs (PWID), who are also affected by the ongoing opioid overdose crisis; gay, bisexual, and other men who have sex with men (gbMSM); immigrants; and incarcerated persons. HCV care cascades can identify gaps in healthcare service provision along the HCV care journey, including: (i)antibody diagnosis, (ii)ribonucleic acid (RNA) testing, (iii)RNA positive diagnosis, (iv)genotyping, (v)treatment and (vi)cure. Large declines in HCV testing and diagnosis rates were reported in British Columbia (BC) and Ontario (ON) at the start of the pandemic, however comprehensive data on the full care cascade are currently unavailable. Data is also lacking on pandemic related changes in HCV care in other Canadian provinces, which are needed to assess and mitigate the effect of the pandemic impacts on the health of people living with HCV in Canada, especially among priority populations. Using testing and administrative data from BC and ON, this project aims to assess the impact of the COVID-19 pandemic and related control measures on (i)HCV care cascades in BC and ON; and (ii)HCV reinfection and death among PWID, gbMSM and immigrants. Surveys conducted among people from priority populations listed above and among healthcare providers will complement care cascade data and provide details on, and practical solutions to, on-the-ground impacts of the pandemic.
Competitiondate
202111
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Janjua, Naveed Z; Binka, Mawuena; Kwong, Jeffrey C; Sander, Beate H
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $497,320~ $0~